INCY:NGS-Incyte Corporation

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 86.03

Change

+0.44 (+0.51)%

Market Cap

USD 18.16B

Volume

2.47M

Yahoo Analyst Target

USD 142.47 (65.61%)

STA Analyst Target

USD 143.19 (66.44%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-02-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TIG TiGenix

+0.92 (+2.20%)

USD 253.14B
AMGN Amgen Inc.

-0.05 (-0.03%)

USD 132.26B
GILD Gilead Sciences Inc.

-0.85 (-1.04%)

USD 105.56B
CELG Celgene Corporation

-0.88 (-0.92%)

USD 71.65B
BIIB Biogen Inc.

-7.51 (-2.51%)

USD 61.75B
SHPG Shire plc

-1.24 (-0.92%)

USD 40.67B
VRTX Vertex Pharmaceuticals Incorpo..

-0.22 (-0.14%)

USD 40.65B
REGN Regeneron Pharmaceuticals Inc.

-1.03 (-0.31%)

USD 35.77B
ALXN Alexion Pharmaceuticals Inc.

-2.24 (-1.83%)

USD 26.71B
GRFS Grifols S.A.

-0.07 (-0.30%)

USD 15.66B

ETFs Containing INCY

IBB iShares Nasdaq Biotechnol.. 2.46 % 0.47 %

-0.40 (-0.36%)

USD 9.67B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.16% 32% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.16% 32% F 19% F
Trailing 12 Months  
Capital Gain -28.42% 32% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.42% 32% F 16% F
Trailing 5 Years  
Capital Gain 291.05% 82% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 291.05% 82% B- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 52.14% 87% B+ 94% A
Dividend Return 52.14% 87% B+ 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 60.59% 38% F 15% F
Risk Adjusted Return 86.06% 98% A+ 77% C+
Market Capitalization 20.12B 98% A+ 97% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 136.80 98% A+ 97% A+
Price/Book Ratio 17.67 10% F 5% F
Price / Cash Flow Ratio 32.59 2% F 2% F
Price/Free Cash Flow Ratio -4,301.50 100% A+ 100% A+
Management Effectiveness  
Return on Equity -14.83% 77% C+ 31% F
Return on Invested Capital -5.63% 82% B- 34% F
Return on Assets -8.52% 86% B 32% F
Debt to Equity Ratio 40.50% 35% F 51% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

INCY:NGS-Incyte Corporation

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 86.03

Change

+0.44 (+0.51)%

Market Cap

USD 18.16B

Volume

2.47M

Yahoo Analyst Target

USD 142.47 (65.61%)

STA Analyst Target

USD 143.19 (66.44%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-02-16